Symptom dimensions are associated with progressive brain volume changes in schizophrenia

Schizophrenia Research

Volumn 138, Issue 2-3, 2012, Pages 171-176

  Collin, G ^a   Derks, E M ^a,b   van Haren, N E M ^a   Schnack, H G ^a   Hulshoff Pol, H E ^a   Kahn, R S ^a   Cahn, W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Cerebellum; Disorganization; Hebephrenia; Magnetic resonance imaging

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; BRAIN REGION; BRAIN SIZE; CEREBELLUM CORTEX; COGNITION; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISORIENTATION; FEMALE; FOLLOW UP; HUMAN; INTELLIGENCE QUOTIENT; MAJOR CLINICAL STUDY; MALE; MANIA; NEUROPATHOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; SYMPTOM;

ADOLESCENT; ADULT; AFFECTIVE SYMPTOMS; BRAIN; CASE-CONTROL STUDIES; DEPRESSION; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGAN SIZE; SCHIZOPHRENIA; SCHIZOPHRENIA, DISORGANIZED; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84862135095     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.03.036     Document Type: Article

References (50)

1. Andreasen N.C., Flaum M., Arndt S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch. Gen. Psychiatry 1992, 49(8):615-623.
2. Andreasen N.C., Paradiso S., O'Leary D.S. "Cognitive dysmetria" as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical-cerebellar circuitry?. Schizophr. Bull. 1998, 24(2):203-218.
3. Andreasen N.C., Nopoulos P., Magnotta V., Pierson R., Ziebell S., Ho B.-C. Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia. Biol. Psychiatry 2011, 70(7):672-679.
4. Bowden N.A., Scott R.J., Tooney P.A. Altered expression of regulator of G-protein signalling 4 (RGS4) mRNA in the superior temporal gyrus in schizophrenia. Schizophr. Res. 2007, 89(1-3):165-168.
5. Brouwer R.M., Hulshoff Pol H.E., Schnack H.G. Segmentation of MRI brain scans using non-uniform partial volume densities. Neuroimage 2010, 49(1):467-477.
6. Buchanan R.W., Carpenter W.T. The neuroanatomies of schizophrenia. Schizophr. Bull. 1997, 23(3):367-372.
7. Cahn W., Rais M., Stigter F.P., van Haren N.E.M., Caspers E., Hulshoff Pol H.E., Xu Z., Schnack H.G., Kahn R.S. Psychosis and brain volume changes during the first five years of schizophrenia. Eur. Neuropsychopharmacol. 2009, 19(2):147-151.
8. DeLisi L.E., Hoff A.L., Sakuma M., Kushner M., Lee G., Kantawala K., Shedlack K., Smith A.M., Tew W., Grimson R. A prospective follow-up study of brain morphology and cognition in 1st episode schizophrenic patients. Biol. Psychiatry 1995, 38:349-360.
9. DeLisi L.E., Grimson R., Sakuma M., Tew W., Kushner M., Hoff A.L. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry research. Neuroimaging 1997, 74:129-140.
10. DeLisi L.E., Sakuma M., Ge S., Kushner M. Association of brain structural change with the heterogeneous course of schizophrenia from early childhood through five years subsequent to a first hospitalization. Psychiatry Res. 1998, 84(2-3):75-88.
11. Derks, E.M., Allardyce, J., Boks, M.P., Vermunt, J.K., Hijman, R., Ophoff, R.A., in press. Kraepelin was right: a latent class analysis of symptom dimensions in patients and controls. Schizophr. Bull. (September 30): 1-11. doi: http://dx.doi.org/10.1093/schbul/sbq103.
12. Dibben C.R.M., Rice C., Laws K., McKenna P.J. Is executive impairment associated with schizophrenic syndromes? A meta-analysis. Psychol. Med. 2009, 39(3):381-392.
13. Flynn J.R. The WAIS-III and WAIS-IV: Daubert motions favor the certainly false over the approximately true. Appl. Neuropsychol. 2009, 16(2):98-104.
14. Gunduz-Bruce H. The acute effects of NMDA antagonism: from the rodent to the human brain. Brain Res. Rev. 2009, 60(2):279-286.
15. Hecker E. Die hebephrenie: ein beitrag zur klinischen Psychiatrie. Arch. Pathol. Anat. Physiol. Klin. Med. 1871, 52:394-429.
16. Ho B.-C., Andreasen N.C., Nopoulos P., Arndt S., Magnotta V., Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch. Gen. Psychiatry 2003, 60(6):585-594.
17. Holliday E.G., McLean D.E., Nyholt D.R., Mowry B.J. Susceptibility locus on chromosome 1q23-25 for a schizophrenia subtype resembling deficit schizophrenia identified by latent class analysis. Arch. Gen. Psychiatry 2009, 66(10):1058-1067.
18. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr. Bull. 2009, 35(3):549-562.
19. Hulshoff Pol H.E., Schnack H.G., Mandl R.C.W., van Haren N.E.M., Koning H., Collins L., Evans A.C., Kahn R.S. Focal gray matter density changes in schizophrenia. Arch. Gen. Psychiatry 2001, 58(12):1118-1125.
20. Hulshoff Pol H.E., Kahn R.S. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr. Bull. 2008, 34(2):354-366.
21. Koutsouleris N., Gaser C., Jäger M., Bottlender R., Frodl T., Holzinger S., Schmitt G.J.E., Zetzsche T., Burgermeister B., Scheuerecker J., Born C., Reiser M., Möller H.-J., Meisenzahl E.M. Structural correlates of psychopathological symptom dimensions in schizophrenia: a voxel-based morphometric study. Neuroimage 2008, 39(4):1600-1612.
22. Kraam A. Classic text no. 77 'Hebephrenia. A contribution to clinical psychiatry' by Dr. Ewald Hecker in Gorlitz (1871). Hist. Psychiatry 2009, 20(1):87-106.
23. Kraepelin E. Dementia-Praecox and Paraphrenia (translated by Barkley RM) 1919, Huntington, New York, NY.
24. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51(3):199-214.
25. Lewis D.A. Antipsychotic medications and brain volume: do we have cause for concern?. Arch. Gen. Psychiatry 2011, 68(2):126-127.
26. Liddle P.F. The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy. Br. J. Psychiatry 1987, 151(2):145-151.
27. Lieberman J., Chakos M., Wu H., Alvir J., Hoffman E., Robinson D., Bilder R. Longitudinal study of brain morphology in first episode schizophrenia. Biol. Psychiatry 2001, 49(6):487-499.
28. McGrath J.A., Avramopoulos D., Lasseter V.K., Wolyniec P.S., Fallin M.D., Liang K.-Y., Nestadt G., Thornquist M.H., Luke J.R., Chen P.-L., Valle D., Pulver A.E. Familiality of novel factorial dimensions of schizophrenia. Arch. Gen. Psychiatry 2009, 66(6):591-600.
29. McIntosh A.M., Owens D.C., Moorhead W.J., Whalley H.C., Stanfield A.C., Hall J., Johnstone E.C., Lawrie S.M. Longitudinal volume reductions in people at high genetic risk of schizophrenia as they develop psychosis. Biol. Psychiatry 2011, 69(10):953-958.
30. Milev P., Ho B.-C., Arndt S., Nopoulos P., Andreasen N.C. Initial magnetic resonance imaging volumetric brain measurements and outcome in schizophrenia: a prospective longitudinal study with 5-year follow-up. Biol. Psychiatry 2003, 54(6):608-615.
31. Nenadic I., Sauer H., Gaser C. Distinct pattern of brain structural deficits in subsyndromes of schizophrenia delineated by psychopathology. Neuroimage 2010, 49(2):1153-1160.
32. Nesvåg R., Saetre P., Lawyer G., Jönsson E.G., Agartz I. The relationship between symptom severity and regional cortical and grey matter volumes in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33(3):482-490.
33. Pantelis C., Yücel M., Wood S.J., Velakoulis D., Sun D., Berger G., Stuart G.W., Yung A., Philips L., McGorry P.D. Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr. Bull. 2005, 31(3):672-696.
34. Peralta V., Cuesta M.J. How many and which are the psychopathological dimensions in schizophrenia? Issues influencing their ascertainment. Schizophr. Res. 2001, 49(3):269-285.
35. Phelan M., Slade M., Thornicroft G., Dunn G., Holloway F., Wykes T., Strathdee G., Loftus L., McCrone P., Hayward P. The Camberwell Assessment of Need: the validity and reliability of an instrument to assess the needs of people with severe mental illness. Br. J. Psychiatry 1995, 167(5):589-595.
36. Picard H., Amado I., Mouchet-Magas S., Olié J.-P., Krebs M.-O. The role of the cerebellum in schizophrenia: an update of clinical, cognitive, and functional evidences. Schizophr. Bull. 2008, 34(1):155-172.
37. Prasad K.M.R., Chowdari K.V., Nimgaonkar V.L., Talkowski M.E., Lewis D.A., Keshavan M.S. Genetic polymorphisms of the RGS4 and dorsolateral prefrontal cortex morphometry among first episode schizophrenia patients. Mol. Psychiatry 2005, 10(2):213-219.
38. Rietkerk T., Boks M.P.M., Sommer I.E., Liddle P.F., Ophoff R.A., Kahn R.S. The genetics of symptom dimensions of schizophrenia: review and meta-analysis. Schizophr. Res. 2008, 102(1-3):197-205.
39. Rodriguez V.M., Catalina M.L., García-Noblejas J.A., Cuesta P. Schizophrenic syndromes and clozapine response in treatment-resistant schizophrenia. Psychiatry Res. 1998, 77(1):21-28.
40. Salokangas R.K.R., Honkonen T., Stengård E., Koivisto A.-M. Symptom dimensions and their association with outcome and treatment setting in long-term schizophrenia. Results of the DSP project. Nord. J. Psychiatry 2002, 56(5):319-327.
41. Schnack H.G., Hulshoff Pol H.E., Baaré W.F., Staal W.G., et al. Automated separation of gray and white matter from MR images of the human brain. Neuroimage 2001, 13(1):230-237.
42. Schnack H.G., Hulshoff Pol H.E., Baaré W.F., Viergever M.A., et al. Automatic segmentation of the ventricular system from MR images of the human brain. Neuroimage 2001, 104(1):95-104.
43. Shenton M.E., Dickey C.C., Frumin M., McCarley R.W. A review of MRI findings in schizophrenia. Schizophr. Res. 2001, 49(1-2):1-52.
44. Sled J.G., Zijdenbos A.P., Evans A.C. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans. Med. Imaging 1998, 17(1):87-97.
45. Stinissen J., Willems P.J., Coetsier P., Hulsman W.L.L. Handleiding bij de Nederlandstalige bewerking van de Wechsler adult intelligence scale (W.A.I.S.). Aanvullende normering van de WAIS voor de leeftijdsgroep van 55 tot 64 jaar (WAIS-NL 1970) 1970, Swets & Zeitlinger, Amsterdam/Lisse.
46. Taylor M.A., Shorter E., Vaidya N.A., Fink M. The failure of the schizophrenia concept and the argument for its replacement by hebephrenia: applying the medical model for disease recognition. Acta Psychiatr. Scand. 2010, 122(3):173-183.
47. van Haren N.E.M., Hulshoff Pol H.E., Schnack H.G., Cahn W., Brans R., Carati I., Rais M., Kahn R.S. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol. Psychiatry 2008, 63(1):106-113.
48. van Haren N.E.M., Hulshoff Pol H.E., Schnack H.G., Cahn W., Mandl R.C.W., Collins D.L., Evans A.C., Kahn R.S. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology 2007, 32(10):2057-2066.
49. Volk D.W., Eggan S.M., Lewis D.A. Alterations in metabotropic glutamate receptor 1α and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia. Am. J. Psychiatry 2010, 167(12):1489-1498.
50. Whitford T.J., Farrow T.F.D., Gomes L., Brennan J., Harris A.W.F., Williams L.M. Grey matter deficits and symptom profile in first episode schizophrenia. Psychiatry Res. 2005, 139(3):229-238.